AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01424098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training program
Description: Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
Study NCT00869713 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Description: All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
Study NCT02647853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel concentration A
Study NCT02647853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel concentration B
Study NCT02647853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00686179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsule, oral, single dose, 6 days
Study NCT00686179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsule(encapsulated), oral, single dose
Study NCT00686179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Capsule, oral, single dose
Study NCT01954732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT01954732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02526836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Surgery
Description: removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
Study NCT02526836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete mesocolic excision with central vascular ligation
Description: excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
Study NCT03200665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound 35-36 (6 / 7 days weeks)
Description: An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
Study NCT04121416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg
Description: induction with 0.3mg/kg of oxycodone in general anesthesia
Study NCT04121416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: induction with 0.3 µg/kg of Sufentanil in general anesthesia
Study NCT00620464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiopaque Implanon
Description: Radiopaque rod for 3 years
Study NCT00620464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon (etonogestrel implant)
Description: Implanon (etonogestrel implant) for 3 years
Study NCT03324672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRIGGER
Description: only TRIGGER point will be included for the manual therapy
Study NCT03324672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRIGGER+CURETAPE
Description: TRIGGER point will be included for the manual therapy with kinesio-taping
Study NCT01387373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine, trastuzumab
Description: Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
Study NCT05357196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PT-112
Description: Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg.
Study NCT03258138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and wellness learning sessions
Description: The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
Study NCT03258138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brainstorming group sessions
Description: The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
Study NCT03258138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual sessions with a multidisciplinary health team
Description: Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
Study NCT03258138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health goal development
Description: Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
Study NCT03258138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition journals
Description: Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
Study NCT04526301 — intervention group
Intervention type: DEVICE
Intervention: Tablo Hemodialysis System
Description: Home hemodialysis treatments \~4 times a week.
Study NCT02207985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Study NCT01119560 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT01119560 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01119560 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01352468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted cognitive training
Description: Four computerized training tasks
Study NCT03123640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation and medication review
Description: Pharmacist performed medication reconciliation and medication review
Study NCT02763631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment
Description: Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
Study NCT02763631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Run In Phase
Description: Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
Study NCT02763631 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Stand Care Arm
Description: No change will be made to participants care
Study NCT02525263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-Kidney Augment
Description: NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
Study NCT04720547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: A nonbenzodiazepine hypnotic
Study NCT04720547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: The Control condition in which participants do not receive medication.
Study NCT04800926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xavier wheelchair controller
Description: Controlling a wheelchair using the Xavier surface EMG system
Study NCT03799224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
Study NCT03799224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY and ATG
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
Study NCT03799224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Study NCT00193492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00193492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT00193492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01861990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: All participants enrolled on valproic acid arm.
Study NCT04153825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
Study NCT04153825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current
Description: Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
Study NCT04153825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
Study NCT04153825 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
Study NCT04153825 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous Electrical Nerve Stimulation
Description: Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
Study NCT04153825 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham interferential Current
Description: Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
Study NCT04590196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longvida curcumin
Description: longvida curcumin verdure sciences formulation
Study NCT04590196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide
Study NCT04346862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine hydrochloride 500mg
Description: The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Study NCT04346862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Study NCT03496298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide (SAR439977)
Description: Pharmaceutical form: Solution for injection,~Route of administration: SC
Study NCT03496298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: SC
Study NCT03910361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
Study NCT03910361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
Study NCT01169272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-SonR 9770
Description: Active implantable defibrillator with capacity of cardiac resynchronization therapy
Study NCT02571530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cerebral Infusion of Trastuzumab
Study NCT04203667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EndoRotor Resection
Description: The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter.
Study NCT01841060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency ablation (RFA)
Description: Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
Study NCT04153539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking along a busy road
Description: The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
Study NCT04153539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking in a traffic-free park
Description: The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
Study NCT00466531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Study NCT00466531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01625390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-6150
Description: Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
Study NCT01625390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa [activated]
Description: comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
Study NCT01352468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Multifaceted cognitive training
Description: Four computerized training tasks
Study NCT04471597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: 5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
Study NCT01625390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-6150
Description: Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
Study NCT00918190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00918190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron, Dexamethasone
Description: Use of ondansetron and dexamethasone as combined antiemetics
Study NCT00918190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, dexamethasone
Description: use of midazolam and dexamethasone as combined antiemetic
Study NCT03163992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
Study NCT02114827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: 23-minute video
Study NCT02114827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAQ Sheet
Study NCT00374621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol with or without isosorbide mononitrate
Description: Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
Study NCT04596761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF-utilizing powered toothbrush
Description: RF-utilizing Powered toothbrush
Study NCT04596761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control placebo with no RF
Description: Placebo control, toothbrush with no RF
Study NCT03753087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10 mg tablet
Study NCT03753087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care with no SGLT-2 inhibitors
Study NCT00410384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study NCT00410384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.